申请人:Dainippon Sumitomo Pharma Co., Ltd.
公开号:US07163936B2
公开(公告)日:2007-01-16
1. A β-lactam compound of the formula [1];
wherein R1 is a lower alkyl, a lower alkyl substituted by a hydroxy; R2 is a hydrogen, a lower alkyl; X is O, S, NH; m and n are 0 to 4, Y1 is a halogen, cyano, a hydroxy, an amino, a lower alkyloxy, a lower alkylamino, a carboxy, a carbamoyl, a lower alkyl, etc., Y2 is hydrogen, an alkyl, cyano, —C(R3)═NR4 (wherein R3 and R4 are hydrogen, an amino, an alkyl, etc., or R3 and R4 may combine each other together with the nitrogen atom to form a 5- to 7-membered heterocyclic group), or a pharmaceutically acceptable salt thereof, or a non-toxic ester thereof, which has an excellent antibacterial activity against Gram-positive bacteria, especially against MRSA and MRCNS.
一种β-内酰胺化合物,其化学式为[1];其中R1为较低的烷基,一种被羟基取代的较低烷基;R2为氢,较低的烷基;X为O、S、NH;m和n为0至4,Y1为卤素、氰基、羟基、氨基、较低的烷氧基、较低的烷基氨基、羧基、氨基甲酰基、较低的烷基等;Y2为氢、烷基、氰基、—C(R3)═NR4(其中R3和R4为氢、氨基、烷基等,或R3和R4可能互相结合形成一个5至7元杂环基),或其药学上可接受的盐或非毒性酯,对革兰氏阳性菌,特别是MRSA和MRCNS具有优异的抗菌活性。